AstraZeneca’s stock market value drops by more than £20bn after the company reports a setback in clinical development for its Wainua drug. According to reports, the treatment does not meet a key target in a study designed to reduce deaths associated with heart disease. The development is viewed by investors as a negative update for the programme, prompting a sharp decline in the company’s market valuation. The reports describe the failure to achieve the specified endpoint as the central reason for the sell-off. AstraZeneca has not been described in the provided coverage as issuing an alternative pathway or immediate change of plans, but the drug setback is presented as significant because it affects an intended objective tied to cardiovascular outcomes. The Wainua trial result therefore influences expectations around the drug’s potential effectiveness and future prospects, which is reflected in the fall in the FTSE 100 company’s share price and market capitalization.